RT Journal Article
SR Electronic
T1 Unravelling the determinants of human health in French Polynesia: the MATAEA project
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.05.23288204
DO 10.1101/2023.04.05.23288204
A1 Teiti, Iotefa
A1 Aubry, Maite
A1 Fernandes-Pellerin, Sandrine
A1 Patin, Etienne
A1 Madec, Yoann
A1 Boucheron, Pauline
A1 Vanhomwegen, Jessica
A1 Torterat, Jérémie
A1 Lastère, Stéphane
A1 Olivier, Sophie
A1 Jaquaniello, Anthony
A1 Roux, Maguelonne
A1 Mendiboure, Vincent
A1 Harmant, Christine
A1 Bisiaux, Aurélie
A1 de León, Gaston Rijo
A1 Liu, Dang
A1 Bossin, Hervé
A1 Mathieu-Daudé, Françoise
A1 Gatti, Clémence
A1 Suhas, Edouard
A1 Chung, Kiyojiken
A1 Condat, Bertrand
A1 Ayotte, Pierre
A1 Prud’homme, Nicolas
A1 Conte, Eric
A1 Jolly, Nathalie
A1 Manugerra, Jean-Claude
A1 Sakuntabhai, Anavaj
A1 Fontanet, Arnaud
A1 Quintana-Murci, Lluis
A1 Cao-Lormeau, Van-Mai
YR 2023
UL http://medrxiv.org/content/early/2023/04/06/2023.04.05.23288204.abstract
AB Background French Polynesia is a French overseas collectivity in the Southeast Pacific, comprising 75 inhabited islands across five archipelagoes. The human settlement of the region corresponds to the last massive migration of humans to empty territories, but its timeline is still debated. Despite their recent population history and geographical isolation, inhabitants of French Polynesia experience health issues similar to those of continental countries. Modern lifestyles and increased longevity have led to a rise in non-communicable diseases (NCDs) such as obesity, diabetes, hypertension, and cardiovascular diseases. Likewise, international trade and people mobility have caused the emergence of communicable diseases (CDs) including mosquito-borne and respiratory diseases. Additionally, chronic pathologies including acute rheumatic fever, liver diseases, and ciguatera, are highly prevalent in French Polynesia. However, data on such diseases are scarce and not representative of the geographic fragmentation of the population.Objectives The MATAEA project aims to estimate the prevalence of several NCDs and CDs in the population of the five archipelagoes, and identify associated risk factors. Moreover, genetic analyses will contribute to determinate the sequence and timings of the peopling history of French Polynesia, and identify causal links between past genetic adaptation to island environments, and present-day susceptibility to certain diseases.Methods This cross-sectional survey is based on the random selection of 2,100 adults aged 18-69 years and residing on 18 islands from the five archipelagoes. Each participant answered a questionnaire on a wide range of topics (including demographic characteristics, lifestyle habits and medical history), underwent physical measurements (height, weight, waist circumference, arterial pressure, and skin pigmentation), and provided biological samples (blood, saliva, and stool) for biological, genetic and microbiological analyses.Conclusion For the first time in French Polynesia, the MATAEA project allows to collect a wide range of data to explore the existence of indicators and/or risk factors for multiple pathologies of public health concern. The results will help health authorities to adapt actions and preventive measures aimed at reducing the incidence of NCDs and CDs. Moreover, the new genomic data generated in this study, combined with anthropological data, will increase our understanding of the peopling history of French Polynesia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe MATAEA project received financial support from La Délégation à la Recherche de la Polynésie française (Convention no. 03557/MED/REC du 29 mai 2019) and the Contrat de Projet Etat-Pays 2015-2020 (Arrêté no. HC/372/DIE/BPT du 18 mai 2018; Convention no. 03298/MTF/REC du 17 mai 2018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The French Comité de protection des personnes (CPP - OUEST III no. 19.08.60 / SI CNRIPH 19.07.02.38421) and the Comité d'Ethique de la Polynésie française (Avis no. 80 CEPF-03/09/2019). gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors